Active Filter(s):
Details:
Hyanutra™-RH Hair Nourishing Shield is a new hair moisturizing conditioner made from HA with different molecular weights and brown rice ferment filtrate by patented technology. It is especially suitable for damaged hair.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Hyanutra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
Hyanutra™-RH Hair Nourishing Shield is a new hair moisturizing conditioner made from HA with different molecular weights and brown rice ferment filtrate by patented technology. It is especially suitable for damaged hair.
Lead Product(s): Hyaluronic Acid
Therapeutic Area: Dermatology Product Name: Hyanutra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2022
Details:
AbateHP™, Bloomage Biotech fully demonstrated the application of sodium hyaluronate in oral beauty, bone and joint maintenance, intestinal health and other fields.
Lead Product(s): Helicobacter Pylori
Therapeutic Area: Infections and Infectious Diseases Product Name: AbateHP
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2022
Details:
Medytox applied for a license for Meditoxin (export name: Neuronox having Clostridium Botulinum Toxin type A), Medytox’s BTX product, to China’s National Medical Products Administration in February 2018.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Neurology Product Name: Neuronox
Highest Development Status: Approved Product Type: Large molecule
Recipient: Medytox
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination August 04, 2022
Details:
The joint venture will be settled in the Haikou National High-tech Zone of south China's Hainan Province, and will focus on research in regenerative medicine and cell culture medium, mesenchymal stem cells-based therapies, as well as related commercial operation.
Lead Product(s): Mesenchymal Stem Cells-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Rohto Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 24, 2022